Aldeyra Therapeutics, Inc.
N/A
USD
N/A
N/A
...
Chart
Financials
Description
ALDX Company Description
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
ALDX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ALDX Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ALDX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ALDX's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of ALDX in WallStreetBets Daily Discussion
ALDX News
Recent insights relating to ALDX
CNBC Recommendations
Recent picks made for ALDX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ALDX
Corporate Flights
Flights by private jets registered to ALDX
Our Analysis